Jon Coren

Dr. Coren acquired his PhD degree in Genetics at the Cornell University in 1991, and he completed his academic and industrial postdoc study at Thomas Jefferson from 1991-1993 and DuPont Merck Pharmaceutical company from 1993 – 1997 respectively. Dr. Coren was the associate professor of Biology at the Elizabesthtown College from 2002 to 2018; during that period, his lab’s research centered on the human genome related studies. In particular, the Coren lab carried out research trying to treat cancers by expressing p53 tumor suppressor gene in human tumor cell lines, and, meanwhile, the lab is also interested in the investigation of the optimal transfection reagent for potential gene therapy studies. In 2012, the lab constructed an arrayed 115,000-member human genomic library encapsulated in the P1 Artificial Chromosome (PAC) shuttle vector pJCPAC-Mam2, which can be utilized in genomic studies like genome-wide association studies (GWAS) in both human and animal cell models hence aiding the validation of gene therapy targets.

Lab Information

Elizabethtown College

Research Area and Skills

Recognize this scientist’s Expertise for their contribution in your research

Human genomic library 0 PAC Cloning vector 0 gene therapies 0 pJCPAC-Mam2 0

More

  • Post
  • Publication
  • Plasmid
  • Following (0)
  • Follower (1)


This guy hasn’t posted anything yet.

Hot Posts for You

Neutralizing antibodies (NAbs) are critical human immune defense mechanisms against viral infections. NAbs can bind to sites on the virus and inhibit entry of that virus into the host. It is a key parameter to evaluate COVID-19 vaccine efficacy per Guidelines from Development and ...Learn More


This 3D animation shows you how DNA is copied in a cell. It shows how both strands of the DNA helix are unzipped and copied to produce two identical DNA molecules. TranscriptDNA is a molecule made up of two strands twisted around each other in a double helix shape. Each strand is ...Learn More


IntroductionA gleam of light finally shone down on the global crisis of the prolonged battle against COVID-19, giving people hopes of preventive care and treatment in the near future by monoclonal antibodies against SARS-CoV-2. As stated the news of NIH’s phase III clinical ...Learn More


"Those who do not know history are obliged to repeat it" This famous phrase that could be from any history teacher to his suspended students has been attributed to great figures in history such as Napoleon or the philosopher George Santayana. In a modern version of it we could say ...Learn More


In recent years there is an increasing number of cytotoxic chemotherapeutic compounds with the ability to rapidly kill dividing cancer cells in preference to non-dividing healthy cells. Nevertheless, the major drawback of chemotherapy is that, in addition to damaging the cancer ...Learn More


The coronavirus pandemic caught everyone unprepared. We had to deal with the fear of an unknown virus which can be lethal for some people. And the whole world just stopped in an attempt to prevent the virus spread.Suddenly we had to adapt to a new way of living, socially isolated ...Learn More


This is the first episode of MolecularCloud Pioneer Scientist interview series. In this interview, MolecularCloud talks with Prof. Shuo Huang from Nanjing University about the recent publications of Dr. Huang’s team and the future prospect of biological nanopore technology. The ...Learn More


The increasing number of confirmed COVID-19 cases is prompting an unprecedented global effort to find a treatment for the disease. Given the fact that a new drug development could be a decade work from initial discovery to the marketplace, scientists are racing to search a cure ...Learn More


The previous article on precision medicine was focused on Pharmacogenomics as a fundamental aspect of cancer therapeutics. In this sequel, emphasis would be on the role of immuno-oncology in personalization of cancer therapy, citing anti PD therapy as an example with hypothetical ...Learn More


  1. Coren, J.S. Retrofitting the BAC cloning vector pBeloBAC11 by the insertion of a mutant loxP site. BMC Res Notes 10, 344 (2017).

  2. Fuesler J, Nagahama Y, Szulewski J, Mundorff J, Bireley S, Coren JS. An arrayed human genomic library constructed in the PAC shuttle vector pJCPAC-Mam2 for genome-wide association studies and gene therapy. Gene. 2012;496(2):103-109. doi:10.1016/j.gene.2012.01.011

  3. Gundersen, E. and Coren, J, 2007. Generating Nested Deletions in PAC Clones Constructed in pJCPAC-Mam2. BIOS 38: 87-94.

  4. Chaterjee, P.K., L.A. Shakes, D.K. Srivastava, D.M. Garland, K.R. Harewood, K.J. Moore and J.S. Coren, 2004. Mutually exclusive recombination of wild-type and mutant loxP sites in vivo facilitates transposon-mediated deletions from both ends of genomic DNA in PACs. NAR 32:5668-5676.

  5. Chaterjee, P.K., S. Mukherjee, L. Shakes, W. Wilson III, J.S. Coren, K.R. Harewood and G. Boyd, 2004. Selecting transpositions using phage P1 headful packaging: new markerless transposons for functionally mapping long-range regulatory sequences in bacterial artificial chromosomes and P1-derived artificial chromosomes. Analytical Biochemistry 335:305-315.


This guy has no following anyone.

Popular Cloud Scientists

Cloud Scientists

About Us · User Accounts and Benefits · Privacy Policy · Management Center · FAQs
© 2024 MolecularCloud